ArticleBMC infectious diseases2025
Modeling the 2022 mpox outbreak with a mechanistic network model.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Compartmental Mathematical Model to Assess the Impact of Vaccination, Isolation, and Key Epidemiological Parameters on Mpox Control.Medical sciences (Basel, Switzerland) · 2025Article
Corrections and comments
- Update of
Authors and funding
2 authors.
Funding
Abstract
backgroundThe 2022 outbreak of mpox affected more than 80,000 individuals worldwide, most of whom were gay, bisexual, and other men who have sex with men (GBMSM) who likely contracted the disease through close contact during sex. Given the unprecedented number of mpox infections and the new route of infection, there was substantial uncertainty about how best to manage the outbreak.
methodsWe implemented a dynamic agent-based network model to simulate the spread of mpox in a United States-based GBMSM population. This model allowed us to implement data-informed dynamic network evolution to simulate realistic disease spreading and behavioral adaptations.
resultsWe found that behavior change, the reduction in one-time partnerships, and widespread vaccination are effective in preventing the transmission of mpox, and that earlier vaccination and behavior adaptation has a greater effect, even when only a high-activity portion of the population participates. With no vaccination or behavior adaptation, 16% of the population was infected (25th percentile, 75th percentiles of simulations: 15.3%, 16.6%). With vaccination and behavior change in only the 25% of GBMSM most likely to have a one-time partner, cumulative infections were reduced by 30%, or a total reduction in nearly 500 infections (mean: 11.3%, [Formula: see text] and [Formula: see text]: 9.4%, 13.4%). Earlier vaccination and behavior adaptation further reduce cumulative infections; beginning vaccination a year before the outbreak results in only 2.6% of GBMSM being infected, averting 1300 infections or nearly 13% of the total population in our model. We also show that sustained partnerships drive the early outbreak, while one-time partnerships drive transmission after the first initial weeks. The median effective reproductive number, [Formula: see text], at [Formula: see text] days is 1.40 for casual partnerships, 1.00 for main, and 0.35 for one-time. By [Formula: see text], the median [Formula: see text] for one-time partnerships more than tripled to 1.47, while it decreases for casual and main partnerships: 0.37 and 0.19, respectively.
conclusionWith the ability to model individuals' behavior, mechanistic networks are particularly well suited to studying sexually transmitted infections, the spread and control of which are often governed by individual-level action. Our results contribute valuable insights into the role of different outbreak mitigation strategies and relationship types in mpox transmission dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.